PET/CT of esophageal cancer: Its role in clinical management

John F. Bruzzi, Reginald F. Munden, Mylene T. Truong, Edith M. Marom, Bradley S. Sabloff, Gregory W. Gladish, Revathy B. Iyer, Tin Su Pan, Homer A. Macapinlac, Jeremy J. Erasmus

Research output: Contribution to journalReview articlepeer-review

122 Scopus citations


Positron emission tomography (PET)/computed tomography (CT) has important utility and limitations in the initial staging of esophageal cancer, evaluation of response to neoadjuvant therapy, and detection of recurrent malignancy. Esophageal cancer is often treated by using a combined modality approach (chemotherapy, radiation therapy, and esophagectomy); correct integration of PET/CT into the conventional work-up of esophageal cancer requires a multidisciplinary approach that combines the information from PET/CT with results of clinical assessment, diagnostic CT, endoscopic gastroduodenoscopy, and endoscopic ultrasonography. PET/CT has limited utility in T staging of esophageal cancer and relatively limited utility in detection of dissemination to locoregional lymph nodes. However, PET/CT allows detection of metastatic disease that may not be identifiable with other methods. PET/CT is not sufficiently reliable in the individual patient for determination of treatment response in the primary tumor. Interpretation of PET/CT results is optimized by understanding the diagnostic limitations and pitfalls that may be encountered, together with knowledge of the natural history of esophageal cancer and the staging and treatment options available.

Original languageEnglish (US)
Pages (from-to)1635-1652
Number of pages18
Issue number6
StatePublished - Nov 2007

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'PET/CT of esophageal cancer: Its role in clinical management'. Together they form a unique fingerprint.

Cite this